Can I Take 5-HTP with Lisinopril?

Lisinopril is a generic ACE (angiotensin-converting enzyme) inhibitor prescribed for hypertension, heart failure, and post-myocardial-infarction management. 5-HTP (5-hydroxytryptophan) is a dietary supplement, chemically the immediate precursor to serotonin, typically derived from Griffonia simplicifolia seed extract. It is sold over the counter and has not been evaluated or approved by the FDA for any medical indication, unlike lisinopril, which carries FDA-approved labeling for the indications above.

The direct answer

There is no documented pharmacokinetic interaction between lisinopril and 5-HTP: lisinopril is not metabolized by the liver's cytochrome P450 enzymes and is excreted unchanged by the kidneys, while 5-HTP is converted to serotonin by aromatic L-amino acid decarboxylase (AADC), a pathway lisinopril does not touch. The two compounds do not compete for metabolism, transport, or protein binding at clinically relevant concentrations. The one area of theoretical overlap is blood pressure: serotonin has complex, receptor-subtype-dependent effects on vascular tone, and some animal and mechanistic research has linked high serotonin exposure to blood pressure changes, but this has not translated into a documented clinically significant interaction with lisinopril in humans at typical supplement doses. The genuine safety issue with 5-HTP is serotonin syndrome, and that risk is driven almost entirely by combining 5-HTP with a second serotonergic prescription drug, not by lisinopril.

How lisinopril works, and why its metabolism matters here

Lisinopril blocks the conversion of angiotensin I to angiotensin II, producing vasodilation, reduced aldosterone secretion, and lower blood pressure. Unlike several other ACE inhibitors (such as enalapril, which is a prodrug requiring hepatic activation), lisinopril is administered in its active form and is cleared largely unchanged by the kidneys rather than through hepatic CYP enzymes. That renal-clearance profile is the reason lisinopril tends to avoid the metabolic conflicts that show up with herbal products or supplements that induce or inhibit CYP enzymes (general lisinopril pharmacology overview; verification against the current product label is recommended before relying on specific pharmacokinetic figures).

ACE inhibitors as a class are recommended as first-line antihypertensive therapy in current U.S. guideline frameworks, particularly for patients with diabetes, chronic kidney disease, or heart failure with reduced ejection fraction. Confirm current guideline specifics and any label updates directly with your prescriber, since guideline recommendations are periodically revised.

How 5-HTP works, and why its target system is different

5-HTP crosses the blood-brain barrier and is converted to serotonin by AADC. It is marketed for mood support, sleep, appetite regulation, and migraine prevention. Small clinical trials have investigated 5-HTP for depressive symptoms, and mechanistic studies have examined its effects on central and peripheral serotonin signaling, but the trial base is limited, sample sizes are small, and 5-HTP is not FDA-approved for treating depression, insomnia, or any other condition. Anyone considering 5-HTP for a specific symptom should treat published trial results as preliminary rather than as an established, dosed therapy.

A separate point worth understanding: roughly 95% of the body's serotonin is located in the gut, not the brain. Oral 5-HTP raises peripheral serotonin levels, and peripheral serotonin affects platelet function, gastrointestinal motility, and vascular tone. This is the mechanistic basis for the theoretical blood-pressure interaction discussed above; it is plausible rather than clinically confirmed in humans at standard supplement doses.

Where the real risk sits: a second serotonergic drug

The documented, clinically significant risk with 5-HTP is serotonin syndrome, a syndrome of excess serotonergic activity that can be life-threatening. It typically requires exposure to a serotonergic agent along with signs such as clonus, agitation, diaphoresis, tremor, or hyperreflexia. Lisinopril has no serotonergic activity and is not classified as a contributor to serotonin syndrome.

Concurrent use of lisinopril with serotonergic drugs raises safety concerns. SSRIs (sertraline, escitalopram, fluoxetine, paroxetine), SNRIs (venlafaxine, duloxetine), MAOIs, tramadol, and triptans all elevate synaptic serotonin via reuptake inhibition, monoamine oxidase inhibition, or direct receptor activation. Combining 5-HTP with these agents may amplify serotonergic signaling to potentially harmful levels. Literature reports have documented serotonin syndrome when 5-HTP was combined with existing serotonergic antidepressants, though specific case references from earlier versions could not be confirmed in primary sources and were therefore excluded to avoid unverified citations. For access to original case reports, consult your pharmacist or physician who can retrieve verified literature through professional database searches.

The FDA has issued safety communications warning that combining serotonergic medications, even at doses individually considered safe, can precipitate serotonin syndrome in susceptible patients. That warning is a general statement about serotonergic drug combinations and is not specific to 5-HTP or to lisinopril, but it is directly relevant to anyone stacking 5-HTP onto an existing serotonergic prescription. Confirm current FDA guidance directly with your pharmacist or prescriber before making a decision, since safety communications are periodically updated.

Blood pressure monitoring if you add 5-HTP to lisinopril

Even without a confirmed drug interaction, any two substances that can independently affect blood pressure deserve a monitoring plan, because symptomatic hypotension (dizziness, fainting, falls) carries real consequences, especially in older adults.

A reasonable, low-burden approach: check blood pressure twice daily for the first two weeks after starting 5-HTP, once before your morning lisinopril dose and once in the evening, and note systolic, diastolic, and heart rate. If systolic pressure drops meaningfully below your usual baseline, or you feel lightheaded on standing, stop the 5-HTP and contact your prescriber rather than adjusting the lisinopril dose yourself. This is a general monitoring practice, not a validated protocol from a specific trial, and it does not substitute for individualized guidance from your own clinician.

There is no pharmacokinetic reason to separate the timing of the two doses. A common practical pattern, lisinopril in the morning, 5-HTP at bedtime, is driven by 5-HTP's reported sleep-related effects and personal routine, not by any requirement to avoid a metabolic conflict.

What to watch for after starting 5-HTP

• Nausea, diarrhea, or abdominal cramping, commonly reported gastrointestinal effects of 5-HTP
• Dizziness on standing, a possible sign of additive blood pressure lowering
• Vivid dreams or sleep disruption, a reported effect of increased serotonergic tone
• Agitation, muscle twitching, tremor, or a fast heart rate, early warning signs of excess serotonergic activity, even without a co-prescribed SSRI or SNRI

Stop 5-HTP and seek urgent medical care if you develop high fever, sustained tremor, muscle rigidity, or confusion. These are hallmark features of serotonin syndrome and require emergency evaluation, not a wait-and-see approach.

If you are already taking both

Ongoing use without problems is reassuring but is not a guarantee against future risk. The risk profile can change the moment a new serotonergic prescription is added, for example, if a clinician who does not know about the 5-HTP prescribes an SSRI for depression. The single most protective step available to a patient is making sure 5-HTP is documented in the pharmacy's medication profile, so that any new serotonergic prescription triggers an automated interaction check.

Evidence-status interaction assessment

Evidence boundary

What is established: lisinopril's mechanism and clearance pathway are well characterized and do not overlap with 5-HTP's metabolism. Serotonin syndrome as a clinical entity, and its association with combining multiple serotonergic drugs, is well established in the toxicology literature.

What is plausible but unproven: a meaningful pharmacodynamic interaction between 5-HTP and lisinopril on blood pressure, beyond a theoretical, dose-dependent mechanism drawn largely from animal and peripheral-serotonin research.

What is not established: any published case of serotonin syndrome or a clinically significant adverse event specifically from the two-drug combination of lisinopril and 5-HTP alone, in the absence of a third serotonergic agent. The absence of such reports is not the same as proof of safety; it may simply reflect the fact that this specific pairing has not been the subject of formal pharmacovigilance study.

Practical guidance

Tell your prescribing clinician and pharmacist before adding 5-HTP, and bring the product label so they can check the dose and any additional ingredients such as vitamin B6. If lisinopril is your only prescription medication, start at a low 5-HTP dose, monitor blood pressure for two weeks, and watch for the warning signs above. If you take any serotonergic prescription drug alongside lisinopril, treat 5-HTP as something to discuss with a physician before starting, not something to add on your own.